Barristers

A local NSW council has been ordered to pay the owners of a block of land it acquired in North-West Sydney $12.7 million, with the court finding that if not for the acquisition, the land could have been used for residential purposes. 

A judge has declined a funder’s bid for a $43 million payout in a class action accusing Colonial First State of charging excessive premiums, saying it was entitled to a 27.5 per cent commission but not $4.5 million for after-the-event insurance. 

A judge has approved a $37.35 million settlement in a class action alleging fintech EML Payments failed to promptly disclose anti-money laundering and counter terrorism compliance concerns.

Bupa has hit back at a class action alleging it provided poor quality care to residents at its aged care facilities, saying it was "not appropriate" to run the case as a group proceeding. 

Developer Holdmark has won an appeal of a council's refusal to allow a site at Macquarie Park in Sydney to be subdivided, paving the way for the development of a new Macquarie Technology data centre.

A judge has disregarded submissions made by a class action solicitor appearing to critique the court's exercise of its procedural powers, “affronted” that the submissions seemed to suggest that she needed to be “educated”.

Developer Garrard Building has succeeded in appealing a regional council's rejection of its plans for a $53 million development in Yamba in the NSW Northern Rivers region due to flood concerns. 

A judge has approved a $50 million settlement in a class action against ANZ and superannuation trustee OnePath, but has slashed by half a proposed $1.76 million deduction for the plaintiff firm's after-the-event insurance.

A judge has ordered McDonald’s to provide any records of discussions among senior management about a court ruling that led to a class action suit over the company’s alleged failure to grant employees 10-minute rest breaks.

A class action against Allergan over recalled breast implants has asked a court to slash parts of the US pharma company’s defence, saying they are "incoherent".